Home › Geographic Atrophy › New Jersey
Geographic Atrophy clinical trials in New Jersey
3 studies for Geographic Atrophy are looking for participants at sites in New Jersey.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Mid Atlantic Retina - Cherry Hill, Cherry Hill
- New Jersey Retina, Teaneck
- New Jersey Retina, Toms River
RecruitingPhase 3
Ages 50 to 85 · All sexes · Updated Sep 18, 2026 · NCT06541704A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
- NJ Retina, Edison
RecruitingPhase 1/2
Ages 50 to 85 · All sexes · Updated Jan 23, 2026 · NCT07158775Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
- Atlantic Eye Physicians, Eatontown
Recruiting
Ages 65 and older · All sexes · Updated Dec 3, 2024 · NCT05438732From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.